Phlow: Addressing the Essential Medicines Supply Chain Crisis
When Americans go to a hospital, visit a doctor, or call for help, they fully expect that the medication they need will be available to them — whether to treat an infection or save a life. It is hard to imagine that a hospital might tell them their cancer treatment has to be delayed for weeks because of a drug shortage, or that the safest and most effective medications for their condition simply aren't available. Phlow, a trailblazing public benefit corporation, is committed to addressing global supply chain issues to end shortages of essential medicines in our country.
Dr. Eric Edwards, co-founder of Phlow, volunteered on a local rescue squad for over 15 years. He saw firsthand what it means to respond to a 911 call without the vital medicines required. In the spring of 2019, Dr. Edwards began working closely with Dr. Frank Gupton, CEO at Virginia Commonwealth University's Medicines for All Institute, to find a solution to the challenges associated with shortages of our country's most essential medicines. Their goal was to understand the current supply chain in order to rebuild critical infrastructure and accelerate the manufacturing of affordable, high-quality medicine in the United States.
By January 2020, Phlow officially launched as a public benefit corporation. "Our goal is to make the U.S. a country where every human being has access to the essential medicines necessary to sustain life and conquer disease," says Dr. Edwards. "Phlow's mission is to reliably supply affordable, high-quality, medicines through U.S.-based advanced manufacturing processes."
When the COVID-19 pandemic hit, Phlow was already positioned to respond. The company turned its entire focus toward medicines in shortage or at risk of disruption. After a thorough and competitive application process, Phlow received federal government funding for advanced manufacturing of essential medicines, including products previously only manufactured abroad.
Today, Phlow and its partners are building the key infrastructure required to establish its end-to-end, U.S.-based supply chain. AMPAC Fine Chemicals, based in Petersburg, presented the perfect opportunity to build out Phlow's vision for its advanced pharmaceutical campus. Construction of the manufacturing campus is underway and will bring multiple state-of-the-art facilities to Petersburg, a designated economic development opportunity zone.
Since its founding, Phlow has been dedicated to ensuring that the care of America's children is not impacted by drug shortages. Dr. Edwards and Dr. Gupton worked closely with Dr. Marshall Summar, Head of Rare Disease Institute at Children's National Hospital, to study essential medicines in shortage in pediatric hospitals. Phlow then launched a one-of-a-kind collaboration called the Children's Hospital Coalition, bringing together some of the top children's hospitals across the nation, including The Children's Hospital of Richmond at VCU, Boston Children's Hospital, Children's Hospital of Philadelphia, and Cincinnati Children's Hospital, among others. Phlow has produced key essential medicines for children, including an injectable diuretic that treats fluid retention and swelling, a corticosteroid to treat disorders of many organ systems, a blood thinner to prevent and treat blood clots, and a medication used to relax the muscles before general anesthesia.
Like TowneBank, Phlow is driven by a strong sense of purpose and committed to improving the lives of all. "We pride ourselves on partnering with those who are mission-aligned," says Dr. Edwards. "TowneBank is focused on basic human values and is committed to serving as a force for good for all stakeholders."
Learn more at Phlow-USA.com.
"Our goal is to make the U.S. a country where every human being has access to the essential medicines necessary to sustain life and conquer disease. Phlow's mission is to reliably supply affordable, high-quality, medicines through U.S.-based advanced manufacturing processes."